Silymarin as hepatoprotector

Silymarin as hepatoprotector
AST was reported by 6 trials. The I2 value being 68%
indicated indispensable heterogeneity. The selected random-
effects model showed that the reduction of AST in SIL treating
group (the SIL combination group and SIL comparing to other
interventions group) was more significant than that of corre-
sponding drugs in control group (AST UI/L: MD = 6.57; 95%
CI, 10.03 to 3.12; P = .0002) (Fig. 2). It was conceivable to
conclude that SIL therapy maintained superior efficacy in
lowering AST level.
Levels of collagen type 1 in hepatic biopsy samples from baboons fed a diet containing 50%
alcohol, with or without concomitant silymarin

Effect of silymarin on antioxidant capacity .This was measured by serum levels of free sulfhydryl groups and
glutathione peroxidase activity in erythrocytes and lymphocytes in patients with alcohol-induced liver disease receiving
silymarin or placebo. SH: sulfhydryl; GSH-Px: glutathione peroxidase. aP\0.05 vs. month 0; bP\0.05 vs. placebo
Changes in alcoholic liver disease and diabetes parameters in patients with diabetes and
alcoholic liver disease receiving standard treatment alone (untreated) or with
concomitant silymarin (treated).
a.Plasma malondialdehyde levels (a marker of membrane peroxidation);
b glycosylated hemoglobin;
c average daily insulin
dose.
Preventive effect on DILI by treatment with the combination of silymarin (420 mg/day) plus
diammonium glycyrrhizinate compared with diammonium glycyrrhizinate alone in patients
with acute lymphoblastic or acute myeloid leukemia undergoing chemotherapy